A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24108849 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Pablo Iglesias und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Laboratory MOL, Departamento de Fisioloxía, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS)…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerases, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia.
Abstract (Originalsprache)
In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. PARP1 has emerged as a target with great therapeutic potential for some tumor types, drawing attention to this enzyme and resulting in many small molecule inhibitors of its enzymatic activity. Therefore, many PARP inhibitors are currently in clinical trials for the treatment of homologous recombination (HR)-deficient tumors, BRCA-related cancers, taking advantage of synthetic lethality. In addition, several novel cellular functions unrelated to its role in DNA repair have been described, including post-translational modification of transcription factors, or acting through protein–protein interactions as a co-activator or co-repressor of transcription. Previously, we reported that this enzyme may play a key role as a transcriptional co-activator of an important component of cell cycle regulation, the transcription factor E2F1. Here, we show that PARP inhibitors, which interfere with its activity in cell cycle regulation, perform this without affecting its enzymatic function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Oncology Laboratory MOL, Departamento de Fisioloxía, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS), Facultade de Medicina, Universidade de Santiago de Compostela and In…
- Departamento de Anatomía Patolóxica e Ciencias Forenses, Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), 15782 Santiago de Compostela, Spain.
ORCID-Profile: Pablo Iglesias, Marcos Seoane, Irene Golán-Cancela, Jose A Costoya
Förderung
- Ministerio de Ciencia e Innovación
- Consellería de Cultura, Educación e Ordenación Universitaria
- Xunta de Galicia
- European Union (European Regional Development Fund–ERDF)
Zitieren
APA
Iglesias, P., Seoane, M., Golán-Cancela, I., Fraga, M., Arce, V. M., & Costoya, J. A. (2023). A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108849
Vancouver
Iglesias P, Seoane M, Golán-Cancela I, Fraga M, Arce VM, Costoya JA. A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108849
BibTeX
@article{Iglesias2023,
author = {Iglesias, Pablo and Seoane, Marcos and Golán-Cancela, Irene and Fraga, Máximo and Arce, Victor M and Costoya, Jose A},
title = {A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24108849}
}
EUVIMED